文献速递白血病

CD200表达标记人急性髓系白血病中的白血病干细胞

CD200 expression marks leukemia stem cells in human AML.
PubMed 文献 · Blood Adv · 2020-01-01

该研究探讨CD200作为急性髓系白血病(AML)白血病干细胞(LSC)标志物的价值。在65例AML样本中,75%(49/65)的CD45dim原始细胞≥10%表达CD200;在10例异种移植实验中,CD200可在9例(90%)中识别LSC。CD200可同时捕获同一AML样本中CD34阴性和阳性LSC,并在NPM1突变AML中富集原始基因表达特征。

要点

  • CD200在多数AML患者的CD45dim原始细胞上表达,可识别LSC。
  • CD200标记可同时捕获CD34阴性和CD34阳性LSC。
  • 在NPM1突变AML中,CD200+富集LSC组分显示原始基因表达特征。

核心结论

  • CD200是一种新型LSC标志物,能够从AML患者样本中捕获包括NPM1突变在内的整个LSC群体。

研究设计与样本

  • 研究分析了65例AML患者样本,并利用异种移植实验评估CD200+细胞的LSC功能。

主要发现

  • CD200在CD45dim原始细胞上的表达比例高于CD45high细胞。
  • 75%(49/65)的AML病例中,≥10%的CD45dim原始细胞表达CD200。
  • 在10例异种移植实验中,CD200在9例(90%)中识别出LSC。
  • CD200可同时捕获同一AML样本中的CD34阴性和CD34阳性LSC。
  • NPM1突变AML的高度纯化CD200+ LSC组分与未分选细胞相比,原始基因表达特征富集。

关键数值与推荐

  • CD200阳性定义为≥10%的CD45dim原始细胞表达CD200。

临床怎么用

  • CD200可用于AML患者样本中LSC的识别与分离,辅助研究LSC异质性和治疗抵抗机制。

局限性

  • 未报告CD200+ LSC分离后功能验证的详细数据及临床预后关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The leukemia stem cell (LSC) populations of acute myeloid leukemia (AML) exhibit phenotypic, genetic, and functional heterogeneity that contribute to therapy failure and relapse. Progress toward understanding the mechanistic basis for therapy resistance in LSCs has been hampered by difficulties in isolating cell fractions that enrich for the entire heterogeneous population of LSCs within individual AML samples. We previously reported that CD200 gene expression is upregulated in LSC-containing AML fractions. Here, we show that CD200 is present on a greater proportion of CD45dim blasts compared with more differentiated CD45high cells in AML patient samples. In 75% (49 of 65) of AML cases we examined, CD200 was expressed on ≥10% of CD45dim blasts; of these, CD200 identified LSCs within the blast population in 9 of 10 (90%) samples tested in xenotransplantation assays. CD200+ LSCs could be isolated from CD200+ normal HSCs with the use of additional markers. Notably, CD200 expression captured both CD34- and CD34+ LSCs within individual AML samples. Analysis of highly purified CD200+ LSC-containing fractions from NPM1-mutated AMLs, which are commonly CD34-, exhibited an enrichment of primitive gene expression signatures compared with unfractionated cells. Overall, our findings support CD200 as a novel LSC marker that is able to capture the entire LSC compartment from AML patient samples, including those with NPM1 mutation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ho JM, Dobson SM, Voisin V, et al. CD200 expression marks leukemia stem cells in human AML. Blood Adv. 2020. PMID: 33147339. doi:10.1182/bloodadvances.2020001802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。